These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 10359140)

  • 1. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
    Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
    J Neurooncol; 1999 Feb; 41(3):205-11. PubMed ID: 10359140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
    Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
    J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas.
    Piva R; Cavalla P; Bortolotto S; Cordera S; Grosso R; Richiardi P; Dutto A; Schiffer D
    Int J Oncol; 1998 Jan; 12(1):55-8. PubMed ID: 9454886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CDKN2A/p16 inactivation in the prognosis of oligodendrogliomas.
    Bortolotto S; Chiadò-Piat L; Cavalla P; Bosone I; Chiò A; Mauro A; Schiffer D
    Int J Cancer; 2000 Nov; 88(4):554-7. PubMed ID: 11058870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of molecular markers in low-grade diffuse astrocytomas: loss of p16 and retinoblastoma protein expression is associated with short survival.
    Hilton DA; Penney M; Evans B; Sanders H; Love S
    Am J Surg Pathol; 2002 Apr; 26(4):472-8. PubMed ID: 11914625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
    Ohgaki H; Kleihues P
    J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 9p deletion and p16, Cyclin D1, and Myc hyperexpression on the outcome of anaplastic oligodendrogliomas.
    Michaud K; de Tayrac M; D'Astous M; Paquet C; Gould PV; Saikali S
    PLoS One; 2018; 13(2):e0193213. PubMed ID: 29489901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Morphologic and molecular genetic aspects of oligodendroglial neoplasms.
    Bigner SH; Rasheed BK; Wiltshire R; McLendon RE
    Neuro Oncol; 1999 Jan; 1(1):52-60. PubMed ID: 11550302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cellular proliferation in pilocytic and diffuse astrocytomas.
    Giannini C; Scheithauer BW; Burger PC; Christensen MR; Wollan PC; Sebo TJ; Forsyth PA; Hayostek CJ
    J Neuropathol Exp Neurol; 1999 Jan; 58(1):46-53. PubMed ID: 10068313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 expression increases with malignancy and indicates unfavourable outcome in astrocytoma.
    Rauscher J; Beschorner R; Gierke M; Bisdas S; Braun C; Ebner FH; Schittenhelm J
    J Clin Pathol; 2014 Jul; 67(7):556-61. PubMed ID: 24607494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours.
    Hara A; Saegusa M; Ichinoe M; Okayasu I
    J Clin Pathol; 2008 Mar; 61(3):287-92. PubMed ID: 18156430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas.
    Okamoto Y; Di Patre PL; Burkhard C; Horstmann S; Jourde B; Fahey M; Schüler D; Probst-Hensch NM; Yasargil MG; Yonekawa Y; Lütolf UM; Kleihues P; Ohgaki H
    Acta Neuropathol; 2004 Jul; 108(1):49-56. PubMed ID: 15118874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
    Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
    Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher YAP1 Levels Are Associated With Shorter Survival of Patients With Low Grade Astrocytoma.
    Dicke J; Hero L; Kuhl S; Görtz L; Goldbrunner R; Timmer M
    Anticancer Res; 2024 Jul; 44(7):3005-3011. PubMed ID: 38925840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
    Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
    Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced apoptosis in pilocytic astrocytoma: a comparative study of apoptosis and proliferation in astrocytic tumors.
    Nakamizo A; Inamura T; Ikezaki K; Yoshimoto K; Inoha S; Mizoguchi M; Amano T; Fukui M
    J Neurooncol; 2002 Apr; 57(2):105-14. PubMed ID: 12125970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiapoptotic Bcl-2 family protein expression increases with progression of oligodendroglioma.
    Deininger MH; Weller M; Streffer J; Meyermann R
    Cancer; 1999 Nov; 86(9):1832-9. PubMed ID: 10547558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of immune defense genes in pilocytic astrocytomas.
    Huang H; Hara A; Homma T; Yonekawa Y; Ohgaki H
    J Neuropathol Exp Neurol; 2005 Oct; 64(10):891-901. PubMed ID: 16215461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.